These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 1974516)

  • 21. Partial dopamine receptor agonists reverse behavioral, biochemical and neuroendocrine effects of neuroleptics in the rat: potential treatment of extrapyramidal side effects.
    Svensson K; Eriksson E; Carlsson A
    Neuropharmacology; 1993 Oct; 32(10):1037-45. PubMed ID: 7905192
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of dextromethorphan on dopamine dependent behaviours in rats.
    Gaikwad RV; Gaonkar RK; Jadhav SA; Thorat VM; Jadhav JH; Balsara JJ
    Indian J Exp Biol; 2007 Aug; 45(8):712-9. PubMed ID: 17877148
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prejunctional inhibitory effect of a dopamine D-2 agonist, N-0437, on vascular adrenergic responses.
    Friedman DJ; Budai D; Krause DN; Duckles SP
    J Pharmacol Exp Ther; 1989 Sep; 250(3):853-9. PubMed ID: 2674420
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of striatal dopamine release by the selective D-2 dopamine receptor agonist N-0437 is blocked by quinine.
    Cass WA; Zahniser NR
    Synapse; 1990; 5(4):336-7. PubMed ID: 2141733
    [No Abstract]   [Full Text] [Related]  

  • 25. Effects of buspirone on dopamine dependent behaviours in rats.
    Dhavalshankh AG; Jadhav SA; Gaikwad RV; Gaonkar RK; Thorat VM; Balsara JJ
    Indian J Physiol Pharmacol; 2007; 51(4):375-86. PubMed ID: 18476392
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of raclopride on exploratory locomotor activity, treadmill locomotion, conditioned avoidance behaviour and catalepsy in rats: behavioural profile comparisons between raclopride, haloperidol and preclamol.
    Hillegaart V; Ahlenius S
    Pharmacol Toxicol; 1987 May; 60(5):350-4. PubMed ID: 3615345
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacological profiles of three new, potent and selective dopamine receptor agonists: N-0434, N-0437 and N-0734.
    Van der Weide J; De Vries JB; Tepper PG; Horn AS
    Eur J Pharmacol; 1986 Jun; 125(2):273-82. PubMed ID: 3743637
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacological profile of a chromanamine analogue (DP-6OH-3CA) of the selective presynaptic dopamine agonist N,N-dipropyl-7-hydroxy-2-aminotetralin.
    Vermue NA; Dijkstra D; Horn AS
    J Pharm Pharmacol; 1988 Aug; 40(8):574-7. PubMed ID: 2907015
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effects of kainic acid and 6-hydroxydopamine lesions, metal ions and GTP on in vitro binding of the D-2 dopamine agonist, [3H]N-0437, to striatal membranes.
    Van der Weide J; De Vries JB; Tepper PG; Horn AS
    Eur J Pharmacol; 1987 Nov; 143(1):101-7. PubMed ID: 3121365
    [TBL] [Abstract][Full Text] [Related]  

  • 30. (-)-2-(N-propyl-N-2-thienylethylamino)-5-hydroxytetralin (N-0923), a selective D2 dopamine receptor agonist demonstrates the presence of D2 dopamine receptors in the mouse vas deferens but not in the rat vas deferens.
    Martin PL; Kelly M; Cusack NJ
    J Pharmacol Exp Ther; 1993 Dec; 267(3):1342-8. PubMed ID: 7903387
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacological profile of non-hydroxylated and ether derivatives of the potent D2-selective agonist N-0437.
    Jansen JM; den Daas I; Rollema H; Swart PJ; Tepper PG; de Vries JB; Horn AS
    Naunyn Schmiedebergs Arch Pharmacol; 1991 Feb; 343(2):134-42. PubMed ID: 1676829
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacological characterization of PD 118717, a putative piperazinyl benzopyranone dopamine autoreceptor agonist.
    Pugsley TA; Christofferson CL; Corbin A; DeWald HA; Demattos S; Meltzer LT; Myers SL; Shih YH; Whetzel SZ; Wiley JN
    J Pharmacol Exp Ther; 1992 Dec; 263(3):1147-58. PubMed ID: 1361570
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Yawning induced by the selective dopamine D2 agonist N-0437 is blocked by the selective dopamine autoreceptor antagonist (+)-UH 232.
    Cooper SJ; Rusk IN; Barber DJ
    Physiol Behav; 1989 Jun; 45(6):1263-6. PubMed ID: 2573095
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models.
    Gardell LR; Vanover KE; Pounds L; Johnson RW; Barido R; Anderson GT; Veinbergs I; Dyssegaard A; Brunmark P; Tabatabaei A; Davis RE; Brann MR; Hacksell U; Bonhaus DW
    J Pharmacol Exp Ther; 2007 Aug; 322(2):862-70. PubMed ID: 17519387
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacological profile of N,N dipropyl-8-hydroxy-3-chromanamine, an oxygen isostere of the dopamine agonist N,N dipropyl-5-hydroxy-2-aminotetralin with enhanced presynaptic selectivity.
    Vermue NA; Kaptein B; Tepper PG; de Vries JB; Horn AS
    Arch Int Pharmacodyn Ther; 1988; 293():37-56. PubMed ID: 3421784
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of the enantiomers of 3-PPP on conditioned avoidance responding in the rat.
    Clark D; Carlsson A; Hjorth S; Engel J; Lindberg P
    Psychopharmacology (Berl); 1983; 81(1):14-7. PubMed ID: 6138790
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CI-943, a potential antipsychotic agent. I. Preclinical behavioral effects.
    Heffner TG; Downs DA; Meltzer LT; Wiley JN; Williams AE
    J Pharmacol Exp Ther; 1989 Oct; 251(1):105-12. PubMed ID: 2571712
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacological specificity of conditioned avoidance response inhibition in rats: inhibition by neuroleptics and correlation to dopamine receptor blockade.
    Arnt J
    Acta Pharmacol Toxicol (Copenh); 1982 Oct; 51(4):321-9. PubMed ID: 6129770
    [TBL] [Abstract][Full Text] [Related]  

  • 39. On the mode of action of 3-(3-hydroxyphenyl)-N-n-propylpiperidine, 3-PPP, and its enantiomers. With particular reference to dopaminergic mechanisms in the central nervous system.
    Hjorth S
    Acta Physiol Scand Suppl; 1983; 517():1-52. PubMed ID: 6138921
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intracranial self-stimulation under a progressive-ratio schedule in rats: effects of strength of stimulation, d-amphetamine, 7-OH-DPAT and haloperidol.
    Depoortere R; Perrault G; Sanger DJ
    Psychopharmacology (Berl); 1999 Mar; 142(3):221-9. PubMed ID: 10208313
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.